- BC PharmaCare will now reimburse REVESTIVE (teduglutide) by Takeda Canada for eligible pediatric and adult patients with Short Bowel Syndrome (SBS) in British Columbia who rely on parenteral support
- The therapy has shown the potential to help some patients reduce dependence on IV nutrition, fluids, and electrolytes, helping ease treatment burden and improve day-to-day quality of life
- SBS is a rare but serious condition affecting ~800 Canadians, often causing dehydration, malnutrition, fatigue, and long-term complications that may require lifelong IV support
- Health Canada approved REVESTIVE for adults in 2015 and later expanded approval to pediatric patients aged ≥1 year, with the latest reimbursement move improving access across British Columbia
Takeaways:
BC’s decision makes REVESTIVE a province‑funded option for both adult and pediatric Short Bowel Syndrome patients who depend on parenteral support, aligning coverage with other Canadian jurisdictions and closing the last major provincial gap.
By reimbursing teduglutide, BC PharmaCare can help some of the roughly 800 Canadians living with SBS reduce IV nutrition, fluids, and electrolyte needs, which may ease daily treatment burden and improve quality of life; this builds on Health Canada’s original 2015 adult approval and the later extension to children aged one year and older.
Source: CA Newswire
